The estimated Net Worth of Michael Ellis is at least $1.1 Milion dollars as of 16 July 2021. Mr. Ellis owns over 21,196 units of Covetrus stock worth over $31,044 and over the last 5 years he sold CVET stock worth over $1,073,564. In addition, he makes $0 as Executive Vice President i President - Europe and North America at Covetrus.
Michael has made over 6 trades of the Covetrus stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 21,196 units of CVET stock worth $521,210 on 16 July 2021.
The largest trade he's ever made was exercising 26,763 units of Covetrus stock on 14 January 2021 worth over $561,755. On average, Michael trades about 5,586 units every 39 days since 2020. As of 16 July 2021 he still owns at least 1,479 units of Covetrus stock.
You can see the complete history of Mr. Ellis stock trades at the bottom of the page.
Michael Ellis serves as Executive Vice President, President - Europe and North America of the Company. From February 2019 until such appointment, Mr. Ellis served as Senior Vice President and President, Europe. Prior to joining the Company, Mr. Ellis served as Chief Financial Officer—Europe, General Manager and Vice President—Europe, and President—Europe of Henry Schein Animal Health at Henry Schein since April 2009. Mr. Ellis is a qualified Fellow Chartered Management Accountant, FCMA, and has a diploma in Business Studies from Sheffield University.
Michael Ellis is 61, he's been the Executive Vice President i President - Europe and North America of Covetrus since 2020. There are 4 older and 20 younger executives at Covetrus. The oldest executive at Covetrus, Inc. is Philip Laskawy, 78, who is the Independent Chairman of the Board.
Michael's mailing address filed with the SEC is 7, Custom House Street, India Street, Portland, Cumberland County, Maine, 04101, United States.
Over the last 5 years, insiders at Covetrus have traded over $10,243,394 worth of Covetrus stock and bought 11,744 units worth $216,180 . The most active insiders traders include Steven Paladino, Benjamin Wolin oraz Philip A Laskawy. On average, Covetrus executives and independent directors trade stock every 10 days with the average trade being worth of $268,798. The most recent stock trade was executed by Rebecca Ann Kidd on 1 October 2022, trading 1,232 units of CVET stock currently worth $25,860.
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions that include, inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software systems for veterinary practitioners and animal-health clinics, client communication services, reminders, data backup services, and hardware sales and support services. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal and equine markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine.
Covetrus executives and other stock owners filed with the SEC include: